A valuation is only as good as its defensibility. We produce independent valuations for transactions, ESOP schemes, regulatory filings, and shareholder actions — built on documented methodology, comparable analysis, and assumptions a diligence room can interrogate without finding holes. Every report is written for the reader who wants to challenge it.
You're raising equity and the term sheet hinges on valuation. We produce an independent number with methodology your investors' advisors can verify — not a founder's aspiration.
Options must be granted at fair value. We value the equity for scheme design and grant pricing, compliant with the applicable regulations.
FEMA, income-tax, or Companies Act filings require a valuation from a registered valuer using prescribed approaches. We deliver reports that clear regulatory review.
Full enterprise and equity valuation for M&A, fundraises, and shareholder transactions — DCF, comparable company and transaction multiples, asset-based approaches triangulated and weighted for your stage and sector.
Fair value determination for option grants, sweat equity, and employee transactions — the number your scheme, your auditors, and the tax authorities all accept.
PPA for business combinations under Ind AS 103 — identifiable intangibles, goodwill computation, and the documentation your auditors require.
Valuations for FEMA (pricing guidelines), income-tax (56(2)(viib) and capital gains), and Companies Act (preferential allotment, buy-back) — by a registered valuer, in the prescribed form.
Independent second opinions on transaction pricing — for boards, audit committees, and minority shareholders who need an objective read.
Value-in-use and fair-value-less-costs models for Ind AS 36 impairment testing, with assumptions your auditors can sign off on.
We define the purpose, standard of value, and premise — then collect financials, management projections, and market data.
Triangulated valuation across approaches, with comparables selected and justified — not cherry-picked.
A diligence-grade report: methodology, assumptions, sensitivities, and limitations, written to be challenged.
We walk your auditors, bankers, or the other side's advisors through the report and defend the conclusions.
DCF, comparable company and transaction multiples, and asset-based approaches — selected and weighted for your company's stage, sector, and the valuation's purpose. Every assumption is documented and sourced.
Valuations for regulatory purposes are signed by a valuer registered under the Companies (Registered Valuers and Valuation) Rules, 2017, in the prescribed form.
Two to three weeks for a standard valuation from complete data. Multi-entity or complex assignments take longer — we confirm the timeline upfront.
That is the design brief. Methodology, comparables, assumptions, and sensitivities are laid out so a buyer's advisor finds answers, not gaps.
Tell us where your company is headed. A partner — not a sales rep — will respond.
Request a consultation